Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Energy expenditure with insulin detemir versus NPH insulin in type 1 diabetes
2006-003060-59Phase 4Terminated
- Sponsor
- Novo Nordisk
- Start
- Sep 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin detemir in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Energy expenditure after each 16-week treatment period. Started Sep 2006; status: terminated.
02
Drugs
insulin detemir
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2006-003060-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003060-59.